LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • Wedbush Is Raising Kiniksa Pharmaceuticals International, plc (KNSA) FY 25 Rev. Estimate To 675.4 M From 640.0 M 10/28/2025 11:49:40 AM
  • Wedbush Is Increasing Kiniksa Pharmaceuticals International, plc (KNSA) Q4 25 Rev. Estimate To 199.9 M From 179.5 M 10/28/2025 11:49:24 AM
  • Wedbush Is Cutting Kiniksa Pharmaceuticals International, plc (KNSA) FY 26 Estimate To 1.22 From 2.43 10/28/2025 11:49:00 AM
  • Wedbush Is Cutting Kiniksa Pharmaceuticals International, plc (KNSA) FY 25 Estimate To 0.88 From 1.30 10/28/2025 11:48:51 AM
  • Wedbush Is Lowering Kiniksa Pharmaceuticals International, plc (KNSA) Q4 25 Estimate To 0.27 From 0.49 10/28/2025 11:48:41 AM
  • Wedbush Reiterates Kiniksa Pharmaceuticals International, plc (KNSA) At Outperform With $48 Up From $44 Price Target 10/28/2025 11:48:18 AM
  • Kiniksa Pharma Q3 Net Income $18.4 Mln; Total Revenue $180.9 Mln 10/28/2025 7:42:57 AM
  • Kiniksa Pharma : FDA Grants Orphan Drug Designation To KPL-387 For Treatment Of Pericarditis By Kiniksa 10/17/2025 9:27:04 AM
  • Kiniksa Pharma: FDA Grants Orphan Drug Designation To KPL-387 For the Treatment Of Pericarditis 10/17/2025 8:44:15 AM
  • Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $36 Price Target 7/21/2025 8:54:14 PM
  • Kiniksa Pharma Announces Details For Phase 2/3 Clinical Trial Of KPL-387 In Recurrent Pericarditis 6/5/2025 7:19:01 AM
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap